Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why AnaptysBio Shares Rose Nearly 14% on Thursday

TheMotleyFool

0 0

Why AnaptysBio Shares Rose Nearly 14% on ThursdayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

Biotech stocks are often seesaw affairs. Exhibit A: AnaptysBio (NASDAQ: ANAB), which enjoyed a 13.5% rise on Thursday. This nice jump comes mere days after a queasy slide due to the highly discouraging results of a key clinical trial for the company.

AnaptysBio and its investors had high hopes for a pipeline drug called imsidolimab, which the company was developing to treat a rare autoimmune disease called palmoplantar pustulosis (PPP).

Image source: Getty Images.

Source Fool.com

Like: 0

ANAB

Teilen